Abstract:
The present invention provides for a sealer/primer that is generally cured at low bake temperatures. The composition utilizes a resin system to provide both conductivity and adhesion of the coating onto plastic substrates. The present invention uses a polyester, such as one that includes unsaturated polyester, in combination with other resins, including an acrylic, crosslinking agent and conductive pigment to create a conductive primer that can be cured at low temperatures. The composition can be applied through traditional application equipment, seals the surface of the substrate to which it is applied, and cures to an acceptable surface for further processing, such as painting.
Abstract:
N-Benzoyl arylsulfonamides having the formula are BCL-X1 inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-X1 inhibiting compositions and methods of promoting apoptosis in a mammal.
Abstract:
Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.
Abstract:
An electronic device may include a liquid crystal display, a photosensor, a light, and a controller. The liquid crystal display may have first and second transparent substrates and a liquid crystal material between the first and second transparent substrates. The photosensor may be on a portion of the first transparent substrate so that the first transparent substrate is between the photosensor and the second transparent substrate, and the light may be configured to provide illumination for the electronic device. The controller may be coupled to the photosensor and the light, and the controller may be configured to vary an intensity of the illumination from the light responsive to an intensity of light incident of the photosensor. Related displays are also discussed.
Abstract:
Compounds of Formula I wherein A1, B1, C1, D1, E1, F1 and L1 are as defined herein, which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mdl-1 protein, such as leukemia and lymphoma, are disclosed.
Abstract:
The present invention provides a kind of permanent magnetic lifting device, which has: a housing, at the bottom of which is a clamping surface for clamping objects; fixed magnet(s), set in housing relatively fixed to housing; a turnable magnet, set in housing relatively turnable to fixed magnet. When turnable magnet is in the first position relative to fixed magnet, the magnetic force generated by fixed magnet and turnable magnet to clamping surface is zero magnetic force; when turnable magnet is in the third position relative to fixed magnet, the magnetic force generated by fixed magnet and turnable magnet to clamping surface is the maximum magnetic force. The permanent magnetic lifting device also has a positioning mechanism for second position to position the turnable magnet in the second position relative to fixed magnet, fixed magnet and turnable magnet generate trial clamping magnetic force to clamping surface for clamping objects on trial.
Abstract:
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
Abstract:
The invention provides vinblastine derivatives represented by the following formula 1 or their physiologically acceptable salts, their preparation, use and pharmaceutical compositions comprising the said derivatives. The said vinblastine derivatives show inhibiting activities against tumor cell lines and can be used as medicaments for treating malignant tumors.
Abstract:
Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.
Abstract:
Compounds of Formula I wherein A1, B1, C1, D1, E1, F1 and L1 are as defined herein, which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl-1 protein, such as leukemia and lymphoma, are disclosed.